LONDON (Alliance News) - Redx Pharma PLC Wednesday said it will present the pre-clinical profile of its Porcupine inhibitor RXC004 at a conference in Germany.
It will present the profile at the European Organisation for Research & Treatment of Cancer, National Cancer Institute, and American Association for Cancer Research Symposium in Munich.
The company said pre-clinical studies are ongoing to determine the effect of RXC004 on the immune response in cancer, and it is progressing studies to prepare the inhibitor for first-in-human trials.
Redx is targeting the commencement of these first-in-human trials in early 2017.
"RXC004 has the potential to become a potent therapy for a subset of biliary, gastric and pancreatic cancer patients. It has also been shown to enhance the efficacy of checkpoint inhibitors, such as anti-PD-1 antibodies. We aim to initiate first-in-human clinical studies for RXC004 early 2017," said Chief Executive Officer Neil Murray in a statement.
Shares in Redx were down 1.6% at 42.30 pence Wednesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
